Cutting-Edge Cancer Vaccines Enhanced by Nanotechnology

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1331

Special Issue Editor


E-Mail Website
Guest Editor
Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1, Higashi, Tsukuba, Ibaraki 305-8566, Japan
Interests: cancer immunotherapy; nanotechnology; cancer vaccine; adjuvant; in situ cancer vaccine; cancer combination therapy; nanoparticle; immune checkpoint inhibitor

Special Issue Information

Dear Colleagues,

Cancer immunotherapies have significantly extended the survival time of cancer patients, revolutionized cancer treatment and opened a new era of cancer treatment. In cancer immunotherapy, cancer vaccines are among the most promising strategies, owing to their ability to educate the body’s immune system to recognize, target and remove tumor cells. Recently, the successful development of COVID-19 mRNA vaccines and dramatic advances in nanotechnologies have led to significant progress in developing cancer vaccines. In particular, nanotechnology can protect the delivery of antigens, enable sustained and efficient antigen delivery to specific targets, enhance immunogenicity and induce specific immune responses. Therefore, nanotechnology has played an indispensable role in the success of various clinical and preclinical vaccines.

In this Special Issue, original research articles and reviews related to the recent advances, current challenges and future perspectives in cutting-edge nanotechnology-based cancer vaccines are welcome. Research areas may include the following:

  1. Nanoscale synthesis, structural regulation and functional design of polymers, lipids, inorganic particles and bio-derived materials for cancer vaccines;
  2. Nano-vaccine adjuvants for therapeutic, prophylactic and in situ cancer vaccines;
  3. Nanotechnology-based cancer vaccines combined with other cancer therapies, such as immune checkpoint inhibitors;
  4. Mechanisms, safety and efficacy of nanotechnology-enhanced cancer vaccines.

I look forward to receiving your contributions.

Dr. Xiupeng Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • nanotechnology
  • cancer vaccine
  • adjuvant
  • in situ cancer vaccine
  • personalized cancer vaccine
  • combination cancer therapy
  • nanoparticle

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 5245 KiB  
Article
Synergistic Effects of Metal–Organic Nanoplatform and Guanine Quadruplex-Based CpG Oligodeoxynucleotides in Therapeutic Cancer Vaccines with Different Tumor Antigens
by Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata
Vaccines 2024, 12(6), 649; https://doi.org/10.3390/vaccines12060649 - 11 Jun 2024
Viewed by 914
Abstract
Oligodeoxynucleotides (ODNs) containing unmethylated cytosine–phosphate–guanosine (CpG) motifs are readily recognized by Toll-like receptor 9 on immune cells, trigger an immunomodulatory cascade, induce a Th1 -biased immune milieu, and have great potential as an adjuvant in cancer vaccines. In this study, a green one-step [...] Read more.
Oligodeoxynucleotides (ODNs) containing unmethylated cytosine–phosphate–guanosine (CpG) motifs are readily recognized by Toll-like receptor 9 on immune cells, trigger an immunomodulatory cascade, induce a Th1 -biased immune milieu, and have great potential as an adjuvant in cancer vaccines. In this study, a green one-step synthesis process was adopted to prepare an amino-rich metal–organic nanoplatform (FN). The synthesized FN nanoplatform can simultaneously and effectively load model tumor antigens (OVA)/autologous tumor antigens (dLLC) and immunostimulatory CpG ODNs with an unmodified PD backbone and a guanine quadruplex structure to obtain various cancer vaccines. The FN nanoplatform and immunostimulatory CpG ODNs generate synergistic effects to enhance the immunogenicity of different antigens and inhibit the growth of established and distant tumors in both the murine E.G7-OVA lymphoma model and the murine Lewis lung carcinoma model. In the E.G7-OVA lymphoma model, vaccination efficiently increases the CD4+, CD8+, and tetramer+CD8+ T cell populations in the spleens. In the Lewis lung carcinoma model, vaccination efficiently increases the CD3+CD4+ and CD3+CD8+ T cell populations in the spleens and CD3+CD8+, CD3CD8+, and CD11b+CD80+ cell populations in the tumors, suggesting the alteration of tumor microenvironments from cold to hot tumors. Full article
(This article belongs to the Special Issue Cutting-Edge Cancer Vaccines Enhanced by Nanotechnology)
Show Figures

Figure 1

Back to TopTop